Evaluation of the pediatric patient for liver transplantation: 2014 practice guideline by the american association for the study of liver diseases, american society of transplantation and the north american society for pediatric gastroenterology, hepatology and nutrition

Hepatology

Volumn 60, Issue 1, 2014, Pages 362-398

  Squires, Robert H ^a,f   Ng, Vicky ^b,g   Romero, Rene ^c,h   Ekong, Udeme ^d   Hardikar, Winita ^e,i   Emre, Sukru ^d   Mazariegos, George V ^a,f  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^g HOSPITAL FOR SICK CHILDREN   (Canada)

^h CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

ⁱ ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; UREA; URSODEOXYCHOLIC ACID;

ACIDEMIA; ACUTE LIVER FAILURE; ALAGILLE SYNDROME; ALPHA 1 ANTITRYPSIN DEFICIENCY; ANESTHESIOLOGY; ARTICLE; AUTOIMMUNE HEPATITIS; BILE ACID SYNTHESIS; BILE DUCT ATRESIA; BLOOD CLOTTING FACTOR 7 DEFICIENCY; BUDD CHIARI SYNDROME; CARDIOPULMONARY FUNCTION; CARDIOPULMONARY INSUFFICIENCY; CHILD NUTRITION; CLINICAL EVALUATION; CREATININE BLOOD LEVEL; CRIGLER NAJJAR SYNDROME; CRYPTOGENIC CIRRHOSIS; CYSTIC FIBROSIS ASSOCIATED LIVER DISEASE; DENTAL CARIES; DUCTAL PLATE MALFORMATION; EXTRAHEPATIC MALIGNANCY; FAMILIAL HYPERCHOLESTEROLEMIA; FATTY ACID OXIDATION; GLYCOGEN STORAGE DISEASE; HEMANGIOENDOTHELIOMA; HEMOPHAGOCYTIC SYNDROME; HEPATOBLASTOMA; HEPATOCYTE TRANSPLANTATION; HEPATOPULMONARY SYNDROME; HUMAN; IMMUNIZATION; INFORMATION RETRIEVAL; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER GRAFT; LIVER TRANSPLANTATION; MEDICAL SOCIETY; MEDICAL STAFF; MENTAL DEVELOPMENT; MITOCHONDRIAL HEPATOPATHY; NIEMANN PICK DISEASE; NONCIRRHOTIC PORTAL HYPERTENSION; NUTRITIONAL ASSESSMENT; OXALOSIS 1; PARENTERAL NUTRITION ASSOCIATED LIVER DISEASE; PATIENT REFERRAL; PEDIATRICS; PORTOPULMONARY HYPERTENSION; PORTOSYSTEMIC ANASTOMOSIS; PRACTICE GUIDELINE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROGRESSIVE FAMILIAL TNTRAHEPATIC CHOLESTASIS; PROTEIN C DEFICIENCY; PSYCHOSOCIAL CARE; SCREENING; SICKLE CELL ANEMIA; SYSTEMIC INFECTION; SYSTEMIC MITOCHONDRIAL DISEASE; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TYROSINEMIA; UREA CYCLE DISORDER; WILSON DISEASE;

CARCINOMA, HEPATOCELLULAR; CHILD; GASTROENTEROLOGY; HEPATOBLASTOMA; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; TISSUE AND ORGAN PROCUREMENT; UNITED STATES;

EID: 84903185479     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27191     Document Type: Article

References (440)

1. Murray KF, Carithers RL, Jr. AASLD practice guidelines: evaluation of the patient for liver transplantation. Hepatology 2005;41:1407-1432.
2. Committee on Bioethics, American Academy of Pediatrics. Informed consent, parental permission, and assent in pediatric practice. Pediatrics 1995;95:314-317.
3. Rivera-Penera T, Moreno J, Skaff C, McDiarmid S, Vargas J, Ament ME. Delayed encephalopathy in fulminant hepatic failure in the pediatric population and the role of liver transplantation. J Pediatr Gastroenter Nutr 1997;24:128-134.
4. Shellmer DA, DeVito Dabbs A, Dew MA, Noll RB, Feldman H, Strauss KA, et al. Cognitive and adaptive functioning after liver transplantation for maple syrup urine disease: a case series. Pediatr Transpl 2011;15:58-64.
5. Agarwala S. Primary malignant liver tumors in children. Indian J Pediatr 2012;79:793-800.
6. Arikan C, Kilic M, Nart D, Ozgenc F, Ozkan T, Tokat Y, et al. Hepatocellular carcinoma in children and effect of living-donor liver transplantation on outcome. Pediatr Transpl 2006;10:42-47.
7. Shneider BL, Brown MB, Haber B, Whitington PF, Schwarz K, Squires R, et al. A multicenter study of the outcome of biliary atresia in the United States, 1997 to 2000. J Pediatr 2006;148:467-474.
8. Cardona J, Houssin D, Gauthier F, Devictor D, Losay J, Hadchouel M, et al. Liver transplantation in children with Alagille syndrome-a study of twelve cases. Transplantation 1995;60:339-342.
9. Kamath BM, Olthoff KM. Liver transplantation in children: update 2010. Pediatr Clin North Am 2010;57:401-414, table of contents.
10. Squires RH. End-stage liver disease in children. Curr Treat Opt Gastroenterol 2001;4:409-421.
11. Giefer MJ, Murray KF, Colletti RB. Pathophysiology, diagnosis, and management of pediatric ascites. J Pediatr Gastroenter Nutr 2011;52:503-513.
12. Gentilini P, Casini-Raggi V, Di Fiore G, Romanelli RG, Buzzelli G, Pinzani M, et al. Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial. J Hepatol 1999;30:639-645.
13. Cardenas A, Gines P. Management of refractory ascites. Clin Gastroenterol Hepatol 2005;3:1187-1191.
14. Kramer RE, Sokol RJ, Yerushalmi B, Liu E, MacKenzie T, Hoffenberg EJ, et al. Large-volume paracentesis in the management of ascites in children. J Pediatr Gastroenter Nutr 2001;33:245-249.
15. Di Giorgio A, Agazzi R, Alberti D, Colledan M, D'Antiga L. Feasibility and efficacy of transjugular intrahepatic portosystemic shunt (TIPS) in children. J Pediatr Gastroenter Nutr 2012;54:594-600.
16. Gana JC, Valentino PL, Morinville V, O'Connor C, Ling SC. Variation in care for children with esophageal varices: a study of physicians', patients', and families' approaches and attitudes. J Pediatr Gastroenter Nutr 2011;52:751-755.
17. D'Antiga L. Medical management of esophageal varices and portal hypertension in children. Semin Pediatr Surg 2012;21:211-218.
18. Shneider BL, Bosch J, de Franchis R, Emre SH, Groszmann RJ, Ling SC, et al. Portal hypertension in children: expert pediatric opinion on the report of the Baveno v Consensus Workshop on Methodology of Diagnosis and Therapy in Portal Hypertension. Pediatr Transpl 2012;16:426-437.
19. Gautam M, Cheruvattath R, Balan V. Recurrence of autoimmune liver disease after liver transplantation: a systematic review. Liver Transpl 2006;12:1813-1824.
20. Siebold L, Dick AA, Thompson R, Maggiore G, Jacquemin E, Jaffe R, et al. Recurrent low gamma-glutamyl transpeptidase cholestasis following liver transplantation for bile salt export pump (BSEP) disease (posttransplant recurrent BSEP disease). Liver Transpl 2010;16:856-863.
21. Miloh T, Arnon R, Shneider B, Suchy F, Kerkar N. A retrospective single-center review of primary sclerosing cholangitis in children. Clin Gastroenterol Hepatol 2009;7:239-245.
22. Hanouneh IA, Macaron C, Lopez R, Zein NN, Lashner BA. Risk of colonic neoplasia after liver transplantation for primary sclerosing cholangitis. Inflamm Bowel Dis 2012;18:269-274.
23. Greer R, Lehnert M, Lewindon P, Cleghorn GJ, Shepherd RW. Body composition and components of energy expenditure in children with endstage liver disease. J Pediatr Gastroenter Nutr 2003;36:358-363.
24. Nightingale S, Ng VL. Optimizing nutritional management in children with chronic liver disease. Pediatr Clin North Am 2009;56:1161-1183.
25. Sultan MI, Leon CD, Biank VF. Role of nutrition in pediatric chronic liver disease. Nutr Clin Pract 2011;26:401-408.
26. Carter-Kent C, Radhakrishnan K, Feldstein AE. Increasing calories, decreasing morbidity and mortality: is improved nutrition the answer to better outcomes in patients with biliary atresia? Hepatology 2007;46:1329-1331.
27. DeRusso PA, Ye W, Shepherd R, Haber BA, Shneider BL, Whitington PF, et al. Growth failure and outcomes in infants with biliary atresia: a report from the Biliary Atresia Research Consortium. Hepatology 2007;46:1632-1638.
28. Sokol RJ, Stall C. Anthropometric evaluation of children with chronic liver disease. Am J Clin Nutr 1990;52:203-208.
29. Sathe MN, Patel AS. Update in pediatrics: focus on fat-soluble vitamins. Nutr Clin Pract 2010;25:340-346.
30. Shneider BL, Magee JC, Bezerra JA, Haber B, Karpen SJ, Raghunathan T, et al. Efficacy of fat-soluble vitamin supplementation in infants with biliary atresia. Pediatrics 2012;130:e607-164.
31. Pettei MJ, Daftary S, Levine JJ. Essential fatty acid deficiency associated with the use of a medium-chain-triglyceride infant formula in pediatric hepatobiliary disease. Am J Clin Nutr 1991;53:1217-1221.
32. Charlton CP, Buchanan E, Holden CE, Preece MA, Green A, Booth IW, et al. Intensive enteral feeding in advanced cirrhosis: reversal of malnutrition without precipitation of hepatic encephalopathy. Arch Dis Child 1992;67:603-607.
33. Holt RI, Miell JP, Jones JS, Mieli-Vergani G, Baker AJ. Nasogastric feeding enhances nutritional status in paediatric liver disease but does not alter circulating levels of IGF-I and IGF binding proteins. Clin Endocrinol (Oxf) 2000;52:217-224.
34. Sullivan JS, Sundaram SS, Pan Z, Sokol RJ. Parenteral nutrition supplementation in biliary atresia patients listed for liver transplantation. Liver Transpl 2012;18:120-128.
35. Perito ER, Glidden D, Roberts JP, Rosenthal P. Overweight and obesity in pediatric liver transplant recipients: prevalence and predictors before and after transplant, United Network for Organ Sharing Data, 1987-2010. Pediatr Transpl 2012;16:41-49.
36. Dick AA, Perkins JD, Spitzer AL, Lao OB, Healey PJ, Reyes JD. Impact of obesity on children undergoing liver transplantation. Liver Transpl 2010;16:1296-1302.
37. Pagadala M, Dasarathy S, Eghtesad B, McCullough AJ. Posttransplant metabolic syndrome: an epidemic waiting to happen. Liver Transpl 2009;15:1662-1670.
38. Rothbaum Perito E, Lau A, Rhee S, Roberts JP, Rosenthal P. Posttransplant metabolic syndrome in children and adolescents after liver transplantation: a systematic review. Liver Transpl 2012;18:1009-1028.
39. Madan N, Arnon R. Evaluation of cardiac manifestations in pediatric liver transplant candidates. Pediatr Transpl 2012;16:318-328.
40. Desai MS, Zainuer S, Kennedy C, Kearney D, Goss J, Karpen SJ. Cardiac structural and functional alterations in infants and children with biliary atresia, listed for liver transplantation. Gastroenterology 2011;141:1264-1272, 72 e1-4.
41. Alves L, Sant'Anna CC, March Mde F, Ferreira S, Marsillac M, Tura M, et al. Preoperative pulmonary assessment of children for liver transplantation. Pediatr Transpl 2008;12:536-540.
42. Dehghani SM, Aleyasin S, Honar N, Eshraghian A, Kashef S, Haghighat M, et al. Pulmonary evaluation in pediatric liver transplant candidates. Indian J Pediatr 2011;78:171-175.
43. Noli K, Solomon M, Golding F, Charron M, Ling SC. Prevalence of hepatopulmonary syndrome in children. Pediatrics 2008;121:e522-527.
44. Arguedas MR, Abrams GA, Krowka MJ, Fallon MB. Prospective evaluation of outcomes and predictors of mortality in patients with hepatopulmonary syndrome undergoing liver transplantation. Hepatology 2003;37:192-197.
45. El-Shabrawi MH, Omran S, Wageeh S, Isa M, Okasha S, Mohsen NA, et al. (99m)Technetium-macroaggregated albumin perfusion lung scan versus contrast enhanced echocardiography in the diagnosis of the hepatopulmonary syndrome in children with chronic liver disease. Eur J Gastroenterol Hepatol 2010;22:1006-1012.
46. Condino AA, Ivy DD, O'Connor JA, Narkewicz MR, Mengshol S, Whitworth JR, et al. Portopulmonary hypertension in pediatric patients. J Pediatr 2005;147:20-26.
47. Krowka MJ, Swanson KL, Frantz RP, McGoon MD, Wiesner RH. Portopulmonary hypertension: results from a 10-year screening algorithm. Hepatology 2006;44:1502-1510.
48. Hayllar KM, Williams SG, Wise AE, Pouria S, Lombard M, Hodson ME, et al. A prognostic model for the prediction of survival in cystic fibrosis. Thorax 1997;52:313-317.
49. Miller MR, Sokol RJ, Narkewicz MR, Sontag MK. Pulmonary function in individuals who underwent liver transplantation: from the US cystic fibrosis foundation registry. Liver Transpl 2012;18:585-593.
50. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med 2006;354:2473-2483.
51. Schwartz GJ, Munoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol 2009;20:629-637.
52. Samyn M, Cheeseman P, Bevis L, Taylor R, Samaroo B, Buxton-Thomas M, et al. Cystatin C, an easy and reliable marker for assessment of renal dysfunction in children with liver disease and after liver transplantation. Liver Transpl 2005;11:344-349.
53. Finney H, Newman DJ, Thakkar H, Fell JM, Price CP. Reference ranges for plasma cystatin C and creatinine measurements in premature infants, neonates, and older children. Arch Dis Child 2000;82:71-5.
54. Akcan-Arikan A, Zappitelli M, Loftis LL, Washburn KK, Jefferson LS, Goldstein SL. Modified RIFLE criteria in critically ill children with acute kidney injury. Kidney Int 2007;71:1028-1035.
55. Chava SP, Singh B, Pal S, Dhawan A, Heaton ND. Indications for combined liver and kidney transplantation in children. Pediatr Transpl 2009;13:661-9.
56. Bartosh SM, Alonso EM, Whitington PF. Renal outcomes in pediatric liver transplantation. Clin Transplant 1997;11(5 Pt 1):354-360.
57. Campbell K, Ng V, Martin S, Magee J, Goebel J, Anand R, Martz K, Bucuvalas J, Group SRFW. Glomerular filtration rate following pediatric liver transplantation-the SPLIT experience. Am J Transpl 2010;10:2673-2682.
58. Paradis K. Tyrosinemia: the Quebec experience. Clin Invest Med 1996;19:311-316.
59. Berg UB, Ericzon BG, Nemeth A. Renal function before and long after liver transplantation in children. Transplantation 2001;72:631-637.
60. Davis ID, Burke B, Freese D, Sharp HL, Kim Y. The pathologic spectrum of the nephropathy associated with alpha 1-antitrypsin deficiency. Hum Pathol 1992;23:57-62.
61. Forget S, Patriquin HB, Dubois J, Lafortune M, Merouani A, Paradis K, et al. The kidney in children with tyrosinemia: sonographic, CT and biochemical findings. Pediatr Radiol 1999;29:104-108.
62. Kamath BM, Yin W, Miller H, Anand R, Rand EB, Alonso E, et al. Outcomes of liver transplantation for patients with alagille syndrome: The studies of pediatric liver transplantation experience. Liver Transpl 2012;18:940-948.
63. Hawwa AF, McKiernan PJ, Shields M, Millership JS, Collier PS, McElnay JC. Influence of ABCB1 polymorphisms and haplotypes on tacrolimus nephrotoxicity and dosage requirements in children with liver transplant. Br J Clin Pharmacol 2009;68:413-21.
64. Morisaki I, Abe K, Tong LS, Kato K, Sobue S. Dental findings of children with biliary atresia: report of seven cases. ASDC J Dent Child 1990;57:220-223.
65. Seow WK, Shepherd RW, Ong TH. Oral changes associated with endstage liver disease and liver transplantation: implications for dental management. ASDC J Dent Child 1991;58:474-480.
66. Guggenheimer J, Eghtesad B, Close JM, Shay C, Fung JJ. Dental health status of liver transplant candidates. Liver Transpl 2007;13:280-286.
67. Shiboski CH, Kawada P, Golinveaux M, Tornabene A, Krishnan S, Mathias R, et al. Oral disease burden and utilization of dental care patterns among pediatric solid organ transplant recipients. J Public Health Dent 2009;69:48-55.
68. Yudkowitz FS, Chietero M. Anesthetic issues in pediatric liver transplantation. Pediatr Transpl 2005;9:666-72.
69. Uejima T. Anesthetic management of the pediatric patient undergoing solid organ transplantation. Anesthesiol Clin North Am 2004;22:809-826.
70. Castaneda-Martinez PD, Alcaide-Ortega RI, Fuentes-Garcia VE, Hernandez-Plata JA, Nieto-Zermeno J, Reyes-Lopez A, et al. Anesthetic risk factors associated with early mortality in pediatric liver transplantation. Transpl Proc 2010;42:2383-2386.
71. Walia A, Mandell MS, Mercaldo N, Michaels D, Robertson A, Banerjee A, et al. Anesthesia for liver transplantation in US academic centers: institutional structure and perioperative care. Liver Transpl 2012;18:737-743.
72. Campbell AL, Herold BC. Immunization of pediatric solid-organ transplantation candidates: immunizations in transplant candidates. Pediatr Transpl 2005;9:652-661.
73. L'Huillier AG, Wildhaber BE, Belli DC, Diana A, Rodriguez M, Siegrist CA, et al. Successful serology-based intervention to increase protection against vaccine-preventable diseases in liver-transplanted children: a 19-yr review of the Swiss national reference center. Pediatr Transpl 2012;16:50-57.
74. Keeffe EB. Hepatitis A and B superimposed on chronic liver disease: vaccine-preventable diseases. Trans Am Clin Climatol Assoc 2006;117:227-237; discussion 237-238.
75. Sternfeld T, Spori-Byrtus V, Riediger C, Langer R, Friess H, Schmid RM, et al. Acute measles infection triggering an episode of liver transplant rejection. Int J Infect Dis 2010;14:e528-530.
76. Wu JF, Ni YH, Chen HL, Hsu HY, Lai HS, Chang MH. Humoral immunogenicity to measles, rubella, and varicella-zoster vaccines in biliary atresia children. Vaccine 2009;27:2812-2815.
77. Kano H, Mizuta K, Sakakihara Y, Kato H, Miki Y, Shibuya N, et al. Efficacy and safety of immunization for pre- and post-liver transplant children. Transplantation 2002;74:543-550.
78. Leise MD, Talwalkar JA. Immunizations in chronic liver disease: what should be done and what is the evidence. Curr Gastroenterol Rep 2013;15:300.
79. Duchini A, Viernes ME, Nyberg LM, Hendry RM, Pockros PJ. Hepatic decompensation in patients with cirrhosis during infection with influenza A. Arch Intern Med 2000;160:113-115.
80. Song JY, Cheong HJ, Ha SH, Hwang IS, Kee SY, Jeong HW, et al. Clinical impact of influenza immunization in patients with liver cirrhosis. J Clin Virol 2007;39:159-163.
81. Danzinger-Isakov L, Kumar D, Practice ASTIDCo. Guidelines for vaccination of solid organ transplant candidates and recipients. Am J Transpl 2009;9(Suppl 4):S258-262.
82. Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et al. 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host. Clin Infect Dis 2014;58:309-318.
83. Burroughs M, Moscona A. Immunization of pediatric solid organ transplant candidates and recipients. Clin Infect Dis 2000;30:857-869.
84. Nkowane BM, Wassilak SG, Orenstein WA, Bart KJ, Schonberger LB, Hinman AR, et al. Vaccine-associated paralytic poliomyelitis. United States: 1973 through 1984. JAMA 1987;257:1335-1340.
85. Allen U, Green M. Prevention and treatment of infectious complications after solid organ transplantation in children. Pediatr Clin North Am 2010;57:459-479, table of contents.
86. Narkewicz MR, Green M, Dunn S, Millis M, McDiarmid S, Mazariegos G, et al. Decreasing incidence of symptomatic Epstein-Barr virus disease and posttransplant lymphoproliferative disorder in pediatric liver transplant recipients: report of the studies of pediatric liver transplantation experience. Liver Transpl 2013;19:730-740.
87. Kotton CN, Kumar D, Caliendo AM, Asberg A, Chou S, Snydman DR, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010;89:779-795.
88. Simon NB, Smith D. Living with chronic pediatric liver disease: the parents' experience. Pediatr Nurs 1992;18:453-458, 489.
89. Cronin DC, Squires J, Squires R, Mazariegos G, Lantos JD. Parental refusal of a liver transplant for a child with biliary atresia. Pediatrics 2013;131:141-146.
90. Hord JD, Rehman W, Hannon P, Anderson-Shaw L, Schmidt ML. Do parents have the right to refuse standard treatment for their child with favorable-prognosis cancer? Ethical and legal concerns. J Clin Oncol 2006;24:5454-5456.
91. Kahana SY, Frazier TW, Drotar D. Preliminary quantitative investigation of predictors of treatment non-adherence in pediatric transplantation: a brief report. Pediatr Transpl 2008;12:656-660.
92. Lurie S, Shemesh E, Sheiner PA, Emre S, Tindle HL, Melchionna L, et al. Non-adherence in pediatric liver transplant recipients-an assessment of risk factors and natural history. Pediatr Transpl 2000;4:200-206.
93. Shaw RJ, Palmer L, Blasey C, Sarwal M. A typology of non-adherence in pediatric renal transplant recipients. Pediatr Transpl 2003;7:489-493.
94. Fisher M, Storfer-Isser A, Shaw RJ, Bernard RS, Drury S, Ularntinon S, et al. Inter-rater reliability of the Pediatric Transplant Rating Instrument (P-TRI): challenges to reliably identifying adherence risk factors during pediatric pre-transplant evaluations. Pediatr Transpl 2011;15:142-147.
95. Fung E, Shaw RJ. Pediatric Transplant Rating Instrument - a scale for the pretransplant psychiatric evaluation of pediatric organ transplant recipients. Pediatr Transpl 2008;12:57-66.
96. Shaw RJ, Taussig HN. Pediatric psychiatric pretransplant evaluation. Clin Child Psychol Psychiatry 1999;4:352-365.
97. Alonso EM, Sorensen LG. Cognitive development following pediatric solid organ transplantation. Curr Opin Organ Transpl 2009;14:522-525.
98. Kaller T, Schulz KH, Sander K, Boeck A, Rogiers X, Burdelski M. Cognitive abilities in children after liver transplantation. Transplantation 2005;79:1252-1256.
99. Sorensen LG, Neighbors K, Martz K, Zelko F, Bucuvalas JC, Alonso EM. Cognitive and academic outcomes after pediatric liver transplantation: Functional Outcomes Group (FOG) results. Am J Transpl 2011;11:303-311.
100. Krull K, Fuchs C, Yurk H, Boone P, Alonso E. Neurocognitive outcome in pediatric liver transplant recipients. Pediatr Transpl 2003;7:111-118.
101. Thevenin DM, Baker A, Kato T, Tzakis A, Fernandez M, Dowling M. Neurodevelopmental outcomes of infant multivisceral transplant recipients: a longitudinal study. Transpl Proc 2006;38:1694-1695.
102. Schulz KH, Wein C, Boeck A, Rogiers X, Burdelski M. Cognitive performance of children who have undergone liver transplantation. Transplantation 2003;75:1236-1240.
103. Wayman KI, Cox KL, Esquivel CO. Neurodevelopmental outcome of young children with extrahepatic biliary atresia 1 year after liver transplantation. J Pediatr 1997;131:894-898.
104. Caudle SE, Katzenstein JM, Karpen S, McLin V. Developmental assessment of infants with biliary atresia: differences between boys and girls. J Pediatr Gastroenter Nutr 2012;55:384-389.
105. Caudle SE, Katzenstein JM, Karpen SJ, McLin VA. Language and motor skills are impaired in infants with biliary atresia before transplantation. J Pediatr 2010;156:936-940, 40 e1.
106. Richards CT, Crawley LM, Magnus D. Use of neurodevelopmental delay in pediatric solid organ transplant listing decisions: inconsistencies in standards across major pediatric transplant centers. Pediatr Transpl 2009;13:843-850.
107. Ohta T, Motoyama O, Takahashi K, Hattori M, Shishido S, Wada N, et al. Kidney transplantation in pediatric recipients with mental retardation: clinical results of a multicenter experience in Japan. Am J Kidney Dis 2006;47:518-257.
108. Lacaille F, Sokal E. Living-related liver transplantation. J Pediatr Gastroenter Nutr 2001;33:431-438.
109. Emre S. Living-donor liver transplantation in children. Pediatr Transpl 2002;6:43-46.
110. Jean-Bernard O. Good Samaritan liver donor in Pediatr Transpl Pediatr Transpl 2009;13:155-159.
111. Wright L, Ross K, Abbey S, Levy G, Grant D. Living anonymous liver donation: case report and ethical justification. Am J Transpl 2007;7:1032-1035.
112. Goldman LS. Liver transplantation using living donors. Preliminary donor psychiatric outcomes. Psychosomatics 1993;34:235-240.
113. Mack CL, Ferrario M, Abecassis M, Whitington PF, Superina RA, Alonso EM. Living donor liver transplantation for children with liver failure and concurrent multiple organ system failure. Liver Transpl 2001;7:890-895.
114. Morioka D, Kasahara M, Takada Y, Corrales JP, Yoshizawa A, Sakamoto S, et al. Living donor liver transplantation for pediatric patients with inheritable metabolic disorders. Am J Transpl 2005;5:2754-2763.
115. Ozcay F, Alehan F, Sevmis S, Karakayali H, Moray G, Torgay A, et al. Living related liver transplantation in Crigler-Najjar syndrome type 1. Transpl Proc 2009;41:2875-2877.
116. El-Karaksy H, Nomachi S, Esmat G, El-Serafy M, Kamel RR, El-Ansary A, et al. Equal outcome of living-related liver transplantation for Wilson's disease from heterozygote and nonheterozygote donors: a report of a brother and sister. Indian J Med Sci 2007;61:286-288.
117. Ishida T, Hiroma T, Hashikura Y, Horiuchi M, Kobayashi K, Nakamura T. Early neonatal onset carbamoyl-phosphate synthase 1 deficiency treated with continuous hemodiafiltration and early living-related liver transplantation. Pediatr Int 2009;51:409-410.
118. Yorifuji T, Kawai M, Mamada M, Kurokawa K, Egawa H, Shigematsu Y, et al. Living-donor liver transplantation for propionic acidaemia. J Inherit Metabol Dis 2004;27:205-210.
119. Marble M, McGoey RR, Mannick E, Keats B, Ng SS, Deputy S, et al. Living related liver transplant in a patient with argininosuccinic aciduria and cirrhosis: metabolic follow-up. J Pediatr Gastroenter Nutr 2008;46:453-456.
120. Cutillo L, Najimi M, Smets F, Janssen M, Reding R, de Ville de Goyet J, et al. Safety of living-related liver transplantation for progressive familial intrahepatic cholestasis. Pediatr Transpl 2006;10:570-574.
121. Tannuri AC, Gibelli NE, Ricardi LR, Santos MM, Maksoud-Filho JG, Pinho-Apezzato ML, et al. Living related donor liver transplantation in children. Transpl Proc 2011;43:161-164.
122. Kasahara M, Kiuchi T, Inomata Y, Uryuhara K, Sakamoto S, Ito T, et al. Living-related liver transplantation for Alagille syndrome. Transplantation 2003;75:2147-2150.
123. Hartley JL, Davenport M, Kelly DA. Biliary atresia. Lancet 2009;374:1704-1713.
124. Petersen C, Harder D, Abola Z, Alberti D, Becker T, Chardot C, et al. European biliary atresia registries: summary of a symposium. Eur J Pediatr Surgery 2008;18:111-116.
125. Davenport M, Puricelli V, Farrant P, Hadzic N, Mieli-Vergani G, Portmann B, et al. The outcome of the older (> or =100 days) infant with biliary atresia. J Pediatr Surg 2004;39:575-581.
126. Sokol RJ, Shepherd RW, Superina R, Bezerra JA, Robuck P, Hoofnagle JH. Screening and outcomes in biliary atresia: summary of a National Institutes of Health workshop. Hepatology 2007;46:566-581.
127. Davenport M, Tizzard SA, Underhill J, Mieli-Vergani G, Portmann B, Hadzic N. The biliary atresia splenic malformation syndrome: a 28-year single-center retrospective study. J Pediatr 2006;149:393-400.
128. Shneider BL, Brown MB, Haber B, Whitington PF, Schwarz K, Squires R, et al. A multicenter study of the outcome of biliary atresia in the United States, 1997 to 2000. J Pediatr 2006;148:467-474.
129. Davenport M, Caponcelli E, Livesey E, Hadzic N, Howard E. Surgical outcome in biliary atresia: etiology affects the influence of age at surgery. Ann Surg 2008;247:694-698.
130. Lee H, Lewis J, Schoen BT, Brand T, Ricketts RR. Kasai portoenterostomy: differences related to race. J Pediatr Surg 2001;36:1196-1198.
131. Schoen BT, Lee H, Sullivan K, Ricketts RR. The Kasai portoenterostomy: when is it too late? J Pediatr Surg 2001;36:97-99.
132. de Vries W, Homan-Van der Veen J, Hulscher JB, Hoekstra-Weebers JE, Houwen RH, Verkade HJ, Netherlands Study Group of Biliary Atresia R. Twenty-year transplant-free survival rate among patients with biliary atresia. Clin Gastroenterol Hepatol 2011;9:1086-1091.
133. Jimenez-Rivera C, Jolin-Dahel KS, Fortinsky KJ, Gozdyra P, Benchimol EI. International incidence and outcomes of biliary atresia. J Pediatr Gastroenter Nutr 2013;56:344-354.
134. Davenport M, Ure BM, Petersen C, Kobayashi H. Surgery for biliary atresia-is there a European consensus? Eur J Pediatr Surg 2007;17:180-183.
135. Kotb MA. Review of historical cohort: ursodeoxycholic acid in extrahepatic biliary atresia. J Pediatr Surg 2008;43:1321-1327.
136. Sarkhy A, Schreiber RA, Milner RA, Barker CC. Does adjuvant steroid therapy post-Kasai portoenterostomy improve outcome of biliary atresia? Systematic review and meta-analysis. Can J Gastroenterol 2011;25:440-444.
137. Bu LN, Chen HL, Chang CJ, Ni YH, Hsu HY, Lai HS, Hsu WM, Chang MH. Prophylactic oral antibiotics in prevention of recurrent cholangitis after the Kasai portoenterostomy. J Pediatr Surg 2003;38:590-593.
138. Luo Y, Zheng S. Current concept about postoperative cholangitis in biliary atresia. World J Pediatr 2008;4:14-19.
139. Bezerra JA, Spino C, Magee JC, Shneider BL, Rosenthal P, Wang KS, et al. High-dose corticosteroid therapy following portoenterostomy in infants with biliary atresia does not improve outcome: the mulit-center, randomized, double-blind, placebo-controlled START Trial. Hepatology 2013;58:263A.
140. Utterson EC, Shepherd RW, Sokol RJ, Bucuvalas J, Magee JC, McDiarmid SV, et al. Biliary atresia: clinical profiles, risk factors, and outcomes of 755 patients listed for liver transplantation. J Pediatr 2005;147:180-185.
141. Barshes NR, Chang IF, Karpen SJ, Carter BA, Goss JA. Impact of pretransplant growth retardation in pediatric liver transplantation. J Pediatr Gastroenter Nutr 2006;43:89-94.
142. Brunati A, Feruzi Z, Sokal E, Smets F, Fervaille C, Gosseye S, et al. Early occurrence of hepatocellular carcinoma in biliary atresia treated by liver transplantation. Pediatr Transpl 2007;11:117-119.
143. Kim JM, Lee SK, Kwon CH, Joh JW, Choe YH, Park CK. Hepatocellular carcinoma in an infant with biliary atresia younger than 1 year. J Pediatr Surg 2012;47:819-821.
144. Romano F, Stroppa P, Bravi M, Casotti V, Lucianetti A, Guizzetti M, et al. Favorable outcome of primary liver transplantation in children with cirrhosis and hepatocellular carcinoma. Pediatr Transpl 2011;15:573-579.
145. Inoue Y, Kato Y, Tamura T, Kobayashi H, Ichikawa S, Lane GJ, et al. Prognostic implications of bile lakes after surgery for biliary atresia. J Pediatr Surg 2008;43:2165-2168.
146. Barshes NR, Lee TC, Balkrishnan R, Karpen SJ, Carter BA, Goss JA. Orthotopic liver transplantation for biliary atresia: the U.S. experience. Liver Transpl 2005;11:1193-1200.
147. Alagille D, Estrada A, Hadchouel M, Gautier M, Odievre M, Dommergues JP. Syndromic paucity of interlobular bile ducts (Alagille syndrome or arteriohepatic dysplasia): review of 80 cases. J Pediatr 1987;110:195-200.
148. Li L, Krantz ID, Deng Y, Genin A, Banta AB, Collins CC, et al. Alagille syndrome is caused by mutations in human Jagged1, which encodes a ligand for Notch1. Nat Genet 1997;16:243-251.
149. Oda T, Elkahloun AG, Pike BL, Okajima K, Krantz ID, Genin A, et al. Mutations in the human Jagged1 gene are responsible for Alagille syndrome. Nat Genet 1997;16:235-242.
150. Watson GH, Miller V. Arteriohepatic dysplasia: familial pulmonary arterial stenosis with neonatal liver disease. Arch Dis Child 1973;48:459-466.
151. Kamath BM, Schwarz KB, Hadzic N. Alagille syndrome and liver transplantation. J Pediatr Gastroenter Nutr 2010;50:11-15.
152. Emerick KM, Rand EB, Goldmuntz E, Krantz ID, Spinner NB, Piccoli DA. Features of Alagille syndrome in 92 patients: frequency and relation to prognosis. Hepatology 1999;29:822-829.
153. Hoffenberg EJ, Narkewicz MR, Sondheimer JM, Smith DJ, Silverman A, Sokol RJ. Outcome of syndromic paucity of interlobular bile ducts (Alagille syndrome) with onset of cholestasis in infancy. J Pediatr 1995;127:220-224.
154. Quiros-Tejeira RE, Ament ME, Heyman MB, Martin MG, Rosenthal P, Hall TR, et al. Variable morbidity in alagille syndrome: a review of 43 cases. J Pediatr Gastroenter Nutr 1999;29:431-437.
155. Lykavieris P, Hadchouel M, Chardot C, Bernard O. Outcome of liver disease in children with Alagille syndrome: a study of 163 patients. Gut 2001;49:431-435.
156. Englert C, Grabhorn E, Burdelski M, Ganschow R. Liver transplantation in children with Alagille syndrome: indications and outcome. Pediatr Transpl 2006;10:154-158.
157. Ovaert C, Germeau C, Barrea C, Moniotte S, Van Obbergh L, Sokal E, et al. Elevated right ventricular pressures are not a contraindication to liver transplantation in Alagille syndrome. Transplantation 2001;72:345-347.
158. Sheflin-Findling S, Arnon R, Lee S, Chu J, Henderling F, Kerkar N, et al. Partial internal biliary diversion for Alagille syndrome: case report and review of the literature. J Pediatr Surg 2012;47:1453-1456.
159. Yang H, Porte RJ, Verkade HJ, De Langen ZJ, Hulscher JB. Partial external biliary diversion in children with progressive familial intrahepatic cholestasis and Alagille disease. J Pediatr Gastroenter Nutr 2009;49:216-221.
160. Modi BP, Suh MY, Jonas MM, Lillehei C, Kim HB. Ileal exclusion for refractory symptomatic cholestasis in Alagille syndrome. J Pediatr Surg 2007;42:800-805.
161. Kamath BM, Loomes KM, Piccoli DA. Medical management of Alagille syndrome. J Pediatr Gastroenter Nutr 2010;50:580-586.
162. Kamath BM, Spinner NB, Emerick KM, Chudley AE, Booth C, Piccoli DA, et al. Vascular anomalies in Alagille syndrome: a significant cause of morbidity and mortality. Circulation 2004;109:1354-1358.
163. Razavi RS, Baker A, Qureshi SA, Rosenthal E, Marsh MJ, Leech SC, et al. Hemodynamic response to continuous infusion of dobutamine in Alagille's syndrome. Transplantation 2001;72:823-828.
164. Arnon R, Annunziato R, Miloh T, Suchy F, Sakworawich A, Sogawa H, et al. Orthotopic liver transplantation for children with Alagille syndrome. Pediatr Transpl 2010;14:622-628.
165. Hori T, Egawa H, Takada Y, Oike F, Kasahara M, Ogura Y, et al. Harambat J, Ranchin B, Dubourg L, Liutkus A, Hadj-Haissa A, Rivet C, Boillot O, Lachaux A, Cochat P. Renal function in pediatric liver transplantation: a long-term follow-up study. Transplantation 2008;86:1028-1034.
166. Roberts EA, Schilsky ML, American Association for Study of Liver D. Diagnosis and treatment of Wilson disease: an update. Hepatology 2008;47:2089-2111.
167. Verma N, Pai G, Hari P, Lodha R. Plasma exchange for hemolytic crisis and acute liver failure in Wilson disease. Indian J Pediatr 2013 [Epub ahead of print].
168. Squires RH Jr, Shneider BL, Bucuvalas J, Alonso E, Sokol RJ, Narkewicz MR, et al. Acute liver failure in children: the first 348 patients in the pediatric acute liver failure study group. J Pediatr 2006;148:652-658.
169. Squires RH, Dhawan A, Alonso E, Narkewicz MR, Shneider BL, Rodriguez-Baez N, et al. Intravenous N-acetylcysteine in pediatric patients with non-acetaminophen acute liver failure: a placebo-controlled clinical trial. Hepatology 2013;57:1542-1549.
170. Lee WS, McKiernan P, Kelly DA. Etiology, outcome and prognostic indicators of childhood fulminant hepatic failure in the United kingdom. J Pediatr Gastroenter Nutr 2005;40:575-581.
171. Navaneethan U, Lancaster E, Venkatesh PG, Wang J, Neff GW. Herpes simplex virus hepatitis - it's high time we consider empiric treatment. J Gastrointest Liver Dis 2011;20:93-96.
172. Rand EB, Karpen SJ, Kelly S, Mack CL, Malatack JJ, Sokol RJ, et al. Treatment of neonatal hemochromatosis with exchange transfusion and intravenous immunoglobulin. J Pediatr 2009;155:566-571.
173. Gregorio GV, Portmann B, Reid F, Donaldson PT, Doherty DG, McCartney M, et al. Autoimmune hepatitis in childhood: a 20-year experience. Hepatology 1997;25:541-547.
174. Lee WM, Squires RH Jr, Nyberg SL, Doo E, Hoofnagle JH. Acute liver failure: summary of a workshop. Hepatology 2008;47:1401-1415.
175. Durand F, Bernuau J, Giostra E, Mentha G, Shouval D, Degott C, et al. Wilson's disease with severe hepatic insufficiency: beneficial effects of early administration of D-penicillamine. Gut. 2001;48:849-852.
176. Narkewicz MR, Dell Olio D, Karpen SJ, Murray KF, Schwarz K, Yazigi N, et al. Pattern of diagnostic evaluation for the causes of pediatric acute liver failure: an opportunity for quality improvement. J Pediatr 2009;155:801-806 e1.
177. Lu BR, Zhang S, Narkewicz MR, Belle SH, Squires RH, Sokol RJ. Evaluation of the liver injury unit scoring system to predict survival in a multinational study of pediatric acute liver failure. J Pediatr 2013;162:1010-1016.
178. Sundaram V, Shneider BL, Dhawan A, Ng VL, Im K, Belle S, Squires RH. King's College Hospital Criteria for non-acetaminophen induced acute liver failure in an international cohort of children. J Pediatr 2013;162:319-323 e1.
179. Mindikoglu AL, King D, Magder LS, Ozolek JA, Mazariegos GV, Shneider BL. Valproic acid-associated acute liver failure in children: case report and analysis of liver transplantation outcomes in the United States. J Pediatr 2011;158:802-807.
180. Ryu JM, Kim KM, Oh SH, Koh KN, Im HJ, Park CJ, Chi HS, Seo JJ. Differential clinical characteristics of acute liver failure caused by hemophagocytic lymphohistiocytosis in children. Pediatr Int 2013;55:748-752.
181. Hery G, Franchi-Abella S, Habes D, Brugieres L, Martelli H, Fabre M, et al. Initial liver transplantation for unresectable hepatoblastoma after chemotherapy. Pediatr Blood Canc 2011;57:1270-1275.
182. Malogolowkin MH, Katzenstein HM, Krailo M, Meyers RL. Treatment of hepatoblastoma: the North American cooperative group experience. Front Biosci (Elite Ed) 2012;4:1717-1723.
183. Otte JB, Pritchard J, Aronson DC, Brown J, Czauderna P, Maibach R, et al. Liver transplantation for hepatoblastoma: results from the International Society of Pediatric Oncology (SIOP) study SIOPEL-1 and review of the world experience. Pediatr Blood Cancer 2004;42:74-83.
184. Aronson DC, Schnater JM, Staalman CR, Weverling GJ, Plaschkes J, Perilongo G, et al. Predictive value of the pretreatment extent of disease system in hepatoblastoma: results from the International Society of Pediatric Oncology Liver Tumor Study Group SIOPEL-1 study. J Clin Oncol 2005;23:1245-1252.
185. Gupta AA, Gerstle JT, Ng V, Wong A, Fecteau A, Malogolowkin MH, et al. Critical review of controversial issues in the management of advanced pediatric liver tumors. Pediatr Blood Cancer 2011;56:1013-1018.
186. Lautz TB, Ben-Ami T, Tantemsapya N, Gosiengfiao Y, Superina RA. Successful nontransplant resection of POST-TEXT III and IV hepatoblastoma. Cancer 2011;117:1976-1983.
187. Austin MT, Leys CM, Feurer ID, Lovvorn HN 3rd, O'Neill JA Jr, Pinson CW, et al. Liver transplantation for childhood hepatic malignancy: a review of the United Network for Organ Sharing (UNOS) database. J Pediatr Surg 2006;41:182-186.
188. Ismail H, Broniszczak D, Kalicinski P, Dembowska-Baginska B, Perek D, Teisseyre J, et al. Changing treatment and outcome of children with hepatoblastoma: analysis of a single center experience over the last 20 years. J Pediatr Surg 2012;47:1331-1339.
189. Kosola S, Lauronen J, Sairanen H, Heikinheimo M, Jalanko H, Pakarinen M. High survival rates after liver transplantation for hepatoblastoma and hepatocellular carcinoma. Pediatr Transpl 2010;14:646-650.
190. Meyers RL, Tiao GM, Dunn SP, Langham MR Jr. Liver transplantation in the management of unresectable hepatoblastoma in children. Front Biosci (Elite Ed) 2012;4:1293-1302.
191. Wen WH, Chang MH, Hsu HY, Ni YH, Chen HL. The development of hepatocellular carcinoma among prospectively followed children with chronic hepatitis B virus infection. J Pediatr 2004;144:397-399.
192. Ismail H, Broniszczak D, Kalicinski P, Markiewicz-Kijewska M, Teisseyre J, Stefanowicz M, et al. Liver transplantation in children with hepatocellular carcinoma. Do Milan criteria apply to pediatric patients? Pediatr Transpl 2009;13:682-692.
193. Yu SB, Kim HY, Eo H, Won JK, Jung SE, Park KW, et al. Clinical characteristics and prognosis of pediatric hepatocellular carcinoma. World J Surg 2006;30:43-50.
194. Malek MM, Shah SR, Atri P, Paredes JL, DiCicco LA, Sindhi R, et al. Review of outcomes of primary liver cancers in children: our institutional experience with resection and transplantation. Surgery. 2010;148:778-782; discussion 82-84.
195. Spangenberg HC, Thimme R, Blum HE. Serum markers of hepatocellular carcinoma. Semin Liver Dis 2006;26:385-390.
196. Mazzaferro V, Bhoori S, Sposito C, Bongini M, Langer M, Miceli R, et al. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. Liver Transpl 2011;17(Suppl 2):S44-57.
197. Beaunoyer M, Vanatta JM, Ogihara M, Strichartz D, Dahl G, Berquist WE, et al. Outcomes of transplantation in children with primary hepatic malignancy. Pediatr Transpl 2007;11:655-660.
198. Christison-Lagay ER, Burrows PE, Alomari A, Dubois J, Kozakewich HP, Lane TS, et al. Hepatic hemangiomas: subtype classification and development of a clinical practice algorithm and registry. J Pediatr Surg 2007;42:62-67; discussion 7-8.
199. Kulungowski AM, Alomari AI, Chawla A, Christison-Lagay ER, Fishman SJ. Lessons from a liver hemangioma registry: subtype classification. J Pediatr Surg 2012;47:165-170.
200. Huang SA, Tu HM, Harney JW, Venihaki M, Butte AJ, Kozakewich HP, et al. Severe hypothyroidism caused by type 3 iodothyronine deiodinase in infantile hemangiomas. N Engl J Med 2000;343:185-189.
201. Kuroda T, Kumagai M, Nosaka S, Nakazawa A, Takimoto T, Hoshino K, et al. Critical infantile hepatic hemangioma: results of a nationwide survey by the Japanese Infantile Hepatic Hemangioma Study Group. J Pediatr Surg 2011;46:2239-2243.
202. Taki M, Ohi C, Yamashita A, Kobayashi M, Kobayashi N, Yoda T, et al. Successful treatment with vincristine of an infant with intractable Kasabach-Merritt syndrome. Pediatr Int 2006;48:82-84.
203. Hu B, Lachman R, Phillips J, Peng SK, Sieger L. Kasabach-Merritt syndrome associated kaposiform hemangio-endothelioma successfully treated with cyclophosphamide, vincristine, and actinomycin D. J Pediatr Hematol Oncol 1998;20:567-569.
204. Debray D, Kelly D, Houwen R, Strandvik B, Colombo C. Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease. J Cystic Fibrosis 2011;10(Suppl 2):S29-36.
205. Colombo C, Battezzati PM, Crosignani A, Morabito A, Costantini D, Padoan R, et al. Liver disease in cystic fibrosis: A prospective study on incidence, risk factors, and outcome. Hepatology 2002;36:1374-1382.
206. Sokol RJ, Durie PR. Recommendations for management of liver and biliary tract disease in cystic fibrosis. Cystic Fibrosis Foundation Hepatobiliary Disease Consensus Group. J Pediatr Gastroenter Nutr 1999;28(Suppl 1):S1-13.
207. Colombo C, Crosignani A, Assaisso M, Battezzati PM, Podda M, Giunta A, et al. Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease: a dose-response study. Hepatology 1992;16:924-930.
208. Colombo C, Battezzati PM, Podda M, Bettinardi N, Giunta A. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis. Hepatology 1996;23:1484-1490.
209. Bhardwaj S, Canlas K, Kahi C, Temkit M, Molleston J, Ober M, et al. Hepatobiliary abnormalities and disease in cystic fibrosis: epidemiology and outcomes through adulthood. J Clin Gastroenterol 2009;43:858-864.
210. Gooding I, Dondos V, Gyi KM, Hodson M, Westaby D. Variceal hemorrhage and cystic fibrosis: outcomes and implications for liver transplantation. Liver Transpl 2005;11:1522-1526.
211. Molmenti EP, Squires RH, Nagata D, Roden JS, Molmenti H, Fasola CG, et al. Liver transplantation for cholestasis associated with cystic fibrosis in the pediatric population. Pediatr Transpl 2003;7:93-97.
212. Horslen S, Sweet S, Gish RG, Shepherd R. Model for endstage liver disease (MELD) exception for cystic fibrosis. Liver Transpl 2006;12(12 Suppl 3):S98-99.
213. Gridelli B. Liver: Benefit of liver transplantation in patients with cystic fibrosis. Nat Rev Gastroenterol Hepatol 2011;8:187-188.
214. Mendizabal M, Reddy KR, Cassuto J, Olthoff KM, Faust TW, Makar GA, et al. Liver transplantation in patients with cystic fibrosis: analysis of United Network for Organ Sharing data. Liver Transpl 2011;17:243-250.
215. Arnon R, Annunziato RA, Miloh T, Padilla M, Sogawa H, Batemarco L, et al. Liver and combined lung and liver transplantation for cystic fibrosis: analysis of the UNOS database. Pediatr Transpl 2011;15:254-624.
216. Fridell JA, Bond GJ, Mazariegos GV, Orenstein DM, Jain A, Sindhi R, et al. Liver transplantation in children with cystic fibrosis: a long-term longitudinal review of a single center's experience. J Pediatr Surg 2003;38:1152-1156.
217. Colombo C, Costantini D, Rocchi A, Romano G, Rossi G, Bianchi ML, et al. Effects of liver transplantation on the nutritional status of patients with cystic fibrosis. Transpl Int 2005;18:246-255.
218. Dowman JK, Watson D, Loganathan S, Gunson BK, Hodson J, Mirza DF, et al. Long-term impact of liver transplantation on respiratory function and nutritional status in children and adults with cystic fibrosis. Am J Transpl 2012;12:954-964.
219. Kuo HT, Lau C, Sampaio MS, Bunnapradist S. Pretransplant risk factors for new-onset diabetes mellitus after transplant in pediatric liver transplant recipients. Liver Transpl 2010;16:1249-1256.
220. Lefaucheur C, Nochy D, Amrein C, Chevalier P, Guillemain R, Cherif M, et al. Renal histopathological lesions after lung transplantation in patients with cystic fibrosis. Am J Transpl 2008;8:1901-1910.
221. Nash EF, Volling C, Gutierrez CA, Tullis E, Coonar A, McRae K, et al. Outcomes of patients with cystic fibrosis undergoing lung transplantation with and without cystic fibrosis-associated liver cirrhosis. Clin Transpl 2012;26:34-41.
222. Nash KL, Collier JD, French J, McKeon D, Gimson AE, Jamieson NV, et al. Cystic fibrosis liver disease: to transplant or not to transplant? Am J Transpl 2008;8:162-169.
223. Haberle J, Boddaert N, Burlina A, Chakrapani A, Dixon M, Huemer M, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders. Orphanet J Rare Dis 2012;7:32.
224. Brusilow SW, Maestri NE. Urea cycle disorders: diagnosis, pathophysiology, and therapy. Advances in pediatrics. 1996;43:127-170.
225. Wilcken B. Problems in the management of urea cycle disorders. Mol Genet Metab 2004;81(Suppl 1):S86-91.
226. McBride KL, Miller G, Carter S, Karpen S, Goss J, Lee B. Developmental outcomes with early orthotopic liver transplantation for infants with neonatal-onset urea cycle defects and a female patient with late-onset ornithine transcarbamylase deficiency. Pediatrics 2004;114:e523-526.
227. Bourdeaux C, Darwish A, Jamart J, Tri TT, Janssen M, Lerut J, et al. Living-related versus deceased donor pediatric liver transplantation: a multivariate analysis of technical and immunological complications in 235 recipients. Am J Transplant 2007;7:440-447.
228. Morioka D, Kasahara M, Takada Y, Shirouzu Y, Taira K, Sakamoto S, et al. Current role of liver transplantation for the treatment of urea cycle disorders: a review of the worldwide English literature and 13 cases at Kyoto University. Liver Transpl 2005;11:1332-1342.
229. Campeau PM, Pivalizza PJ, Miller G, McBride K, Karpen S, Goss J, et al. Early orthotopic liver transplantation in urea cycle defects: follow up of a developmental outcome study. Mol Genet Metab 2010;100(Suppl 1):S84-87.
230. Leonard JV, McKiernan PJ. The role of liver transplantation in urea cycle disorders. Mol Genet Metab 2004;81(Suppl 1):S74-78.
231. Morioka D, Takada Y, Kasahara M, Ito T, Uryuhara K, Ogawa K, et al. Living donor liver transplantation for noncirrhotic inheritable metabolic liver diseases: impact of the use of heterozygous donors. Transplantation 2005;80:623-628.
232. Wakiya T, Sanada Y, Urahashi T, Ihara Y, Yamada N, Okada N, et al. Living donor liver transplantation from an asymptomatic mother who was a carrier for ornithine transcarbamylase deficiency. Pediatr Transpl 2012;16:E196-200.
233. Jansen PL. Diagnosis and management of Crigler-Najjar syndrome. Eur J Pediatr 1999;158(Suppl 20:S89-94.
234. O'Reilly C, Dixon R. Crigler-Najjar syndrome: treatment at home with phototherapy. Scott Med J. 1988;33:335-336.
235. Strauss KA, Robinson DL, Vreman HJ, Puffenberger EG, Hart G, Morton DH. Management of hyperbilirubinemia and prevention of kernicterus in 20 patients with Crigler-Najjar disease. Eur J Pediatr 2006;165:306-319.
236. Mowat AP. Liver disorders in children: the indications for liver replacement in parenchymal and metabolic diseases. Transplant Proc 1987;19:3236-3241.
237. van der Veere CN, Sinaasappel M, McDonagh AF, Rosenthal P, Labrune P, Odievre M, et al. Current therapy for Crigler-Najjar syndrome type 1: report of a world registry. Hepatology 1996;24:311-315.
238. Mieli-Vergani G, Vergani D. Autoimmune hepatitis in children: what is different from adult AIH? Semin Liver Dis 2009;29:297-306.
239. Gregorio GV, Portmann B, Karani J, Harrison P, Donaldson PT, Vergani D, et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 2001;33:544-553.
240. Mieli-Vergani G, Heller S, Jara P, Vergani D, Chang MH, Fujisawa T, et al. Autoimmune hepatitis. J Pediatr Gastroenter Nutr 2009;49:158-164.
241. Martin SR, Alvarez F, Anand R, Song C, Yin W. Outcomes in children who underwent transplantation for autoimmune hepatitis. Liver Transpl 2011;17:393-401.
242. Schramm C, Bubenheim M, Adam R, Karam V, Buckels J, O'Grady JG, et al. Primary liver transplantation for autoimmune hepatitis: a comparative analysis of the European Liver Transplant Registry. Liver Transpl 2010;16:461-469.
243. Heffron TG, Smallwood GA, Oakley B, Pillen T, Welch D, Connor K, et al. Adult and pediatric liver transplantation for autoimmune hepatitis. Transpl Proc 2003;35:1435-1436.
244. Czaja AJ. Autoimmune hepatitis after liver transplantation and other lessons of self-intolerance. Liver Transpl 2002;8:505-513.
245. Molmenti EP, Netto GJ, Murray NG, Smith DM, Molmenti H, Crippin JS, et al. Incidence and recurrence of autoimmune/alloimmune hepatitis in liver transplant recipients. Liver Transpl 2002;8:519-526.
246. Mieli-Vergani G, Vergani D. Autoimmune paediatric liver disease. World J Gastroenterol 2008;14:3360-3367.
247. Liberal R, Grant CR, Mieli-Vergani G, Vergani D. Autoimmune hepatitis: a comprehensive review. J Autoimmun 2013;41:126-139.
248. Boberg KM, Chapman RW, Hirschfield GM, Lohse AW, Manns MP, Schrumpf E, International Autoimmune Hepatitis G. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol 2011;54:374-385.
249. LaRusso NF, Shneider BL, Black D, Gores GJ, James SP, Doo E, et al. Primary sclerosing cholangitis: summary of a workshop. Hepatology 2006;44:746-764.
250. Manns MP. Immunoglobulin G4-associated cholangitis: dominating immunoglobulin G4-positive clones within the B-cell receptor repertoire indicate light at the end of a long tunnel. Hepatology 2013;57:2110-2113.
251. Umemura T, Zen Y, Hamano H, Kawa S, Nakanuma Y, Kiyosawa K. Immunoglobin G4-hepatopathy: association of immunoglobin G4-bearing plasma cells in liver with autoimmune pancreatitis. Hepatology 2007;46:463-471.
252. Ibrahim SH, Zhang L, Freese DK. A 3-year-old with immunoglobulin G4-associated cholangitis. J Pediatr Gastroenterol Nutr 2011;53:109-111.
253. Miloh T, Anand R, Yin W, Vos M, Kerkar N, Alonso E. Pediatric liver transplantation for primary sclerosing cholangitis. Liver Transpl 2011;17:925-933.
254. Bjornsson E, Angulo P. Cholangiocarcinoma in young individuals with and without primary sclerosing cholangitis. Am J Gastroenterol 2007;102:1677-1682.
255. McDiarmid SV, Anand R. Studies of Pediatric Liver Transplantation (SPLIT): a summary of the 2003 Annual Report. Clin Transpl 2003:119-130.
256. Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010;51:660-678.
257. Bambha K, Kim WR, Talwalkar J, Torgerson H, Benson JT, Therneau TM, et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology. 2003;125:1364-1369.
258. Chai PF, Lee WS, Brown RM, McPartland JL, Foster K, McKiernan PJ, et al. Childhood autoimmune liver disease: indications and outcome of liver transplantation. J Pediatr Gastroenter Nutr 2010;50:295-302.
259. Kubitz R, Bode J, Erhardt A, Graf D, Kircheis G, Muller-Stover I, et al. Cholestatic liver diseases from child to adult: the diversity of MDR3 disease. Z Gastroenterol 2011;49:728-736.
260. Alissa FT, Jaffe R, Shneider BL. Update on progressive familial intrahepatic cholestasis. J Pediatr Gastroenter Nutr 2008;46:241-252.
261. Liu C, Aronow BJ, Jegga AG, Wang N, Miethke A, Mourya R, et al. Novel resequencing chip customized to diagnose mutations in patients with inherited syndromes of intrahepatic cholestasis. Gastroenterology 2007;132:119-126.
262. Verhulst PM, van der Velden LM, Oorschot V, van Faassen EE, Klumperman J, Houwen RH, et al. A flippase-independent function of ATP8B1, the protein affected in familial intrahepatic cholestasis type 1, is required for apical protein expression and microvillus formation in polarized epithelial cells. Hepatology 2010;51:2049-2060.
263. Davit-Spraul A, Fabre M, Branchereau S, Baussan C, Gonzales E, Stieger B, et al. ATP8B1 and ABCB11 analysis in 62 children with normal gamma-glutamyl transferase progressive familial intrahepatic cholestasis (PFIC): phenotypic differences between PFIC1 and PFIC2 and natural history. Hepatology 2010;51:1645-1655.
264. Schukfeh N, Metzelder ML, Petersen C, Reismann M, Pfister ED, Ure BM, et al. Normalization of serum bile acids after partial external biliary diversion indicates an excellent long-term outcome in children with progressive familial intrahepatic cholestasis. J Pediatr Surg 2012;47:501-505.
265. Colombo C, Vajro P, Degiorgio D, Coviello DA, Costantino L, Tornillo L, et al. Clinical features and genotype-phenotype correlations in children with progressive familial intrahepatic cholestasis type 3 related to ABCB4 mutations. J Pediatr Gastroenter Nutr 2011;52:73-83.
266. Hori T, Egawa H, Takada Y, Ueda M, Oike F, Ogura Y, et al. Liver disease in alpha-1 antitrypsin deficiency: current understanding and future therapy. COPD 2013;10(Suppl 1):35-43.
267. Sveger T. Liver disease in alpha1-antitrypsin deficiency detected by screening of 200, 000 infants. N Engl J Med 1976;294:1316-1321.
268. Sveger T, Eriksson S. The liver in adolescents with alpha 1-antitrypsin deficiency. Hepatology 1995;22:514-517.
269. Ibarguen E, Gross CR, Savik SK, Sharp HL. Liver disease in alpha-1-antitrypsin deficiency: prognostic indicators. J Pediatr 1990;117:864-870.
270. Volpert D, Molleston JP, Perlmutter DH. Alpha1-antitrypsin deficiency-associated liver disease progresses slowly in some children. J Pediatr Gastroenter Nutr 2000;31:258-263.
271. Hadzic N, Quaglia A, Mieli-Vergani G. Hepatocellular carcinoma in a 12-year-old child with PiZZ alpha1-antitrypsin deficiency. Hepatology 2006;43:194.
272. Hidvegi T, Ewing M, Hale P, Dippold C, Beckett C, Kemp C, et al. An autophagy-enhancing drug promotes degradation of mutant alpha1-antitrypsin Z and reduces hepatic fibrosis. Science 2010;329:229-232.
273. Jankowska I, Socha P. Progressive familial intrahepatic cholestasis and inborn errors of bile acid synthesis. Clin Res Hepatol Gastroenterol 2012;36:271-274.
274. Bove KE, Heubi JE, Balistreri WF, Setchell KD. Bile acid synthetic defects and liver disease: a comprehensive review. Pediatr Dev Pathol 2004;7:315-334.
275. Clayton PT. Disorders of bile acid synthesis. J Inherit Metabol Dis 2011;34:593-604.
276. Setchell KD, Heubi JE. Defects in bile acid biosynthesis-diagnosis and treatment. J Pediatr Gastroenterol Nutr 2006;43(Suppl 1):S17-22.
277. Sundaram SS, Bove KE, Lovell MA, Sokol RJ. Mechanisms of disease: Inborn errors of bile acid synthesis. Nat Clin Pract Gastroenterol Hepatol 2008;5:456-468.
278. Haas D, Gan-Schreier H, Langhans CD, Rohrer T, Engelmann G, Heverin M, et al. Differential diagnosis in patients with suspected bile acid synthesis defects. World J Gastroenterol 2012;18:1067-1076.
279. Gonzales E, Gerhardt MF, Fabre M, Setchell KD, Davit-Spraul A, Vincent I, et al. Oral cholic acid for hereditary defects of primary bile acid synthesis: a safe and effective long-term therapy. Gastroenterology 2009;137:1310-1320 e1-3.
280. Mizuochi T, Kimura A, Ueki I, Takahashi T, Hashimoto T, Takao A, et al. Molecular genetic and bile acid profiles in two Japanese patients with 3beta-hydroxy-DELTA5-C27-steroid dehydrogenase/isomerase deficiency. Pediatr Res 2010;68:258-263.
281. Subramaniam P, Clayton PT, Portmann BC, Mieli-Vergani G, Hadzic N. Variable clinical spectrum of the most common inborn error of bile acid metabolism-3beta-hydroxy-Delta 5-C27-steroid dehydrogenase deficiency. J Pediatr Gastroenter Nutr 2010;50:61-66.
282. Croffie JM, Gupta SK, Chong SK, Fitzgerald JF. Tyrosinemia type 1 should be suspected in infants with severe coagulopathy even in the absence of other signs of liver failure. Pediatrics 1999;103:675-678.
283. Arnon R, Annunziato R, Miloh T, Wasserstein M, Sogawa H, Wilson M, et al. Liver transplantation for hereditary tyrosinemia type I: analysis of the UNOS database. Pediatr Transpl 2011;15:400-405.
284. Koelink CJ, van Hasselt P, van der Ploeg A, van den Heuvel-Eibrink MM, Wijburg FA, Bijleveld CM, et al. Tyrosinemia type I treated by NTBC: how does AFP predict liver cancer? Mol Genet Metab 2006;89:310-315.
285. de Laet C, Dionisi-Vici C, Leonard JV, McKiernan P, Mitchell G, Monti L, et al. Recommendations for the management of tyrosinaemia type 1. Orphanet J Rare Dis 2013;8:8.
286. Shin YS. Glycogen storage disease: clinical, biochemical, and molecular heterogeneity. Semin Pediatr Neurol 2006;13:115-120.
287. Maheshwari A, Rankin R, Segev DL, Thuluvath PJ. Outcomes of liver transplantation for glycogen storage disease: a matched-control study and a review of literature. Clin Transplant 2012;26:432-436.
288. Froissart R, Piraud M, Boudjemline AM, Vianey-Saban C, Petit F, Hubert-Buron A, et al. Glucose-6-phosphatase deficiency. Orphanet J Rare Dis 2011;6:27.
289. Lerut JP, Ciccarelli O, Sempoux C, Danse E, deFlandre J, Horsmans Y, et al. Glycogenosis storage type I diseases and evolutive adenomatosis: an indication for liver transplantation. Transpl Int 2003;16:879-884.
290. Kishnani PS, Austin SL, Arn P, Bali DS, Boney A, Case LE, et al. Glycogen storage disease type III diagnosis and management guidelines. Genet Med 2010;12:446-463.
291. Karwowski C, Galambos C, Finegold D, Shneider BL. Markedly elevated serum transaminases in glycogen storage disease type III. J Pediatr Gastroenter Nutr 2011;52:621-623.
292. Matern D, Starzl TE, Arnaout W, Barnard J, Bynon JS, Dhawan A, et al. Liver transplantation for glycogen storage disease types I, III, and IV. Eur J Pediatr 1999;158(Suppl 2):S43-48.
293. Willot S, Marchand V, Rasquin A, Alvarez F, Martin SR. Systemic progression of type IV glycogen storage disease after liver transplantation. J Pediatr Gastroenter Nutr 2010;51:661-664.
294. Ban HR, Kim KM, Jang JY, Kim GH, You HW, Kim K, et al. Living donor liver transplantation in a Korean child with glycogen storage disease type IV and a GBE1 mutation. Gut Liver 2009;3:60-63.
295. Selby R, Starzl TE, Yunis E, Todo S, Tzakis AG, Brown BI, et al. Liver transplantation for type I and type IV glycogen storage disease. Eur J Pediatr 1993;152(Suppl 1):S71-76.
296. Davis MK, Weinstein DA. Liver transplantation in children with glycogen storage disease: controversies and evaluation of the risk/benefit of this procedure. Pediatr Transpl 2008;12:137-145.
297. Rinaldo P, Matern D, Bennett MJ. Fatty acid oxidation disorders. Annu Rev Physiol 2002;64:477-502.
298. Herrema H, Derks TG, van Dijk TH, Bloks VW, Gerding A, Havinga R, et al. Disturbed hepatic carbohydrate management during high metabolic demand in medium-chain acyl-CoA dehydrogenase (MCAD)-deficient mice. Hepatology 2008;47:1894-1904.
299. Baruteau J, Levade T, Redonnet-Vernhet I, Mesli S, Bloom MC, Broue P. Hypoketotic hypoglycemia with myolysis and hypoparathyroidism: an unusual association in medium chain acyl-CoA desydrogenase deficiency (MCADD). J Pediatr Endocrinol Metabol 2009;22:1175-1177.
300. Bonnet D, Martin D, Pascale De L, Villain E, Jouvet P, Rabier D, et al. Arrhythmias and conduction defects as presenting symptoms of fatty acid oxidation disorders in children. Circulation 1999;100:2248-2253.
301. van Adel BA, Tarnopolsky MA. Metabolic myopathies: update 2009. J Clin Neuromusc Dis 2009;10:97-121.
302. Shneider BL, Rinaldo P, Emre S, Bucuvalas J, Squires R, Narkewicz M, et al. Abnormal concentrations of esterified carnitine in bile: a feature of pediatric acute liver failure with poor prognosis. Hepatology 2005;41:717-721.
303. Rinaldo P. Fatty acid transport and mitochondrial oxidation disorders. Semin Liver Dis 2001;21:489-500.
304. Ibdah JA, Bennett MJ, Rinaldo P, Zhao Y, Gibson B, Sims HF, et al. A fetal fatty-acid oxidation disorder as a cause of liver disease in pregnant women. N Engl J Med 1999;340:1723-1731.
305. Tyni T, Palotie A, Viinikka L, Valanne L, Salo MK, von Dobeln U, et al. Long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency with the G1528C mutation: clinical presentation of thirteen patients. J Pediatr 1997;130:67-76.
306. Sze YK, Dhawan A, Taylor RM, Bansal S, Mieli-Vergani G, Rela M, et al. Pediatric liver transplantation for metabolic liver disease: experience at King's College Hospital. Transplantation 2009;87:87-93.
307. Watts RW. The clinical spectrum of the primary hyperoxalurias and their treatment. J Nephrol 1998;11(Suppl 1):4-7.
308. Bobrowski AE, Langman CB. The primary hyperoxalurias. Semin Nephrol 2008;28:152-162.
309. Cochat P, Hulton SA, Acquaviva C, Danpure CJ, Daudon M, De Marchi M, et al. Primary hyperoxaluria Type 1: indications for screening and guidance for diagnosis and treatment. Nephrol Dial Transpl 2012;27:1729-1736.
310. Cochat P, Liutkus A, Fargue S, Basmaison O, Ranchin B, Rolland MO. Primary hyperoxaluria type 1: still challenging! Pediatr Nephrol 2006;21:1075-1081.
311. Mor E, Nesher E, Ben-Ari Z, Weissman I, Shaharabani E, Eizner S, et al. Sequential liver and kidney transplantation from a single living donor in two young adults with primary hyperoxaluria type 1. Liver Transpl 2013;19:646-648.
312. Kemper MJ. The role of preemptive liver transplantation in primary hyperoxaluria type 1. Urol Res 2005;33:376-379.
313. Seashore MR. The organic acidemias: an overview. In: Pagon RA, Bird TD, Dolan CR, Stephens K, Adam MP, editors. GeneReviews. Seattle, WA. 2009.
314. Strauss KA, Mazariegos GV, Sindhi R, Squires R, Finegold DN, Vockley G, et al. Elective liver transplantation for the treatment of classical maple syrup urine disease. Am J Transpl 2006;6:557-564.
315. Chen PW, Hwu WL, Ho MC, Lee NC, Chien YH, Ni YH, et al. Stabilization of blood methylmalonic acid level in methylmalonic acidemia after liver transplantation. Pediatr Transpl 2010;14:337-341.
316. Strauss KA, Wardley B, Robinson D, Hendrickson C, Rider NL, Puffenberger EG, et al. Classical maple syrup urine disease and brain development: principles of management and formula design. Mol Genet Metab 2010;99:333-345.
317. Mazariegos GV, Morton DH, Sindhi R, Soltys K, Nayyar N, Bond G, et al. Liver transplantation for classical maple syrup urine disease: long-term follow-up in 37 patients and comparative United Network for Organ Sharing experience. J Pediatr 2012;160:116-121 e1.
318. Khanna A, Hart M, Nyhan WL, Hassanein T, Panyard-Davis J, Barshop BA. Domino liver transplantation in maple syrup urine disease. Liver Transpl 2006;12:876-882.
319. Schuff-Werner P, Fenger S, Kohlschein P. Role of lipid apheresis in changing times. Clin Res Cardiol Suppl 2012;7(Suppl 1):7-14.
320. Maiorana A, Nobili V, Calandra S, Francalanci P, Bernabei S, El Hachem M, et al. Preemptive liver transplantation in a child with familial hypercholesterolemia. Pediatr Transpl 2011;15:E25-29.
321. Lee WS, Sokol RJ. Mitochondrial hepatopathies: advances in genetics and pathogenesis. Hepatology 2007;45:1555-1565.
322. Lee WS, Sokol RJ. Liver disease in mitochondrial disorders. Semin Liver Dis 2007;27:259-273.
323. Darwish AA, McKiernan P, Chardot C. Paediatric liver transplantation for metabolic disorders. Part 2: Metabolic disorders with liver lesions. Clin Res Hepatol Gastroenterol 2011;35:271-280.
324. Munnich A, Rustin P. Clinical spectrum and diagnosis of mitochondrial disorders. Am J Med Genet 2001;106:4-17.
325. Ferrari G, Lamantea E, Donati A, Filosto M, Briem E, Carrara F, et al. Infantile hepatocerebral syndromes associated with mutations in the mitochondrial DNA polymerase-gammaA. Brain 2005;128(Pt 4):723-731.
326. Milone M, Massie R. Polymerase gamma 1 mutations: clinical correlations. Neurologist 2010;16:84-91.
327. Tsao CY, Mendell JR, Luquette M, Dixon B, Morrow G 3rd. Mitochondrial DNA depletion in children. J Child Neurol 2000;15:822-824.
328. Rake JP, van Spronsen FJ, Visser G, Ruitenbeek W, Schweizer JJ, Bijleveld CM, et al. End-stage liver disease as the only consequence of a mitochondrial respiratory chain deficiency: no contra-indication for liver transplantation. Eur J Pediatr 2000;159:523-526.
329. Thomson M, McKiernan P, Buckels J, Mayer D, Kelly D. Generalised mitochondrial cytopathy is an absolute contraindication to orthotopic liver transplant in childhood. J Pediatr Gastroenter Nutr 1998;26:478-481.
330. Tzoulis C, Engelsen BA, Telstad W, Aasly J, Zeviani M, Winterthun S, et al. The spectrum of clinical disease caused by the A467T and W748S POLG mutations: a study of 26 cases. Brain 2006;129(Pt 7):1685-1692.
331. Dhawan A, Mieli-Vergani G. Liver transplantation for mitochondrial respiratory chain disorders: to be or not to be? Transplantation 2001;71:596-598.
332. Dubern B, Broue P, Dubuisson C, Cormier-Daire V, Habes D, Chardot C, et al. Orthotopic liver transplantation for mitochondrial respiratory chain disorders: a study of 5 children. Transplantation 2001;71:633-637.
333. Sokal EM, Sokol R, Cormier V, Lacaille F, McKiernan P, Van Spronsen FJ, et al. Liver transplantation in mitochondrial respiratory chain disorders. Eur J Pediatr 1999;158(Suppl 2):S81-84.
334. Delarue A, Paut O, Guys JM, Montfort MF, Lethel V, Roquelaure B, et al. Inappropriate liver transplantation in a child with Alpers-Huttenlocher syndrome misdiagnosed as valproate-induced acute liver failure. Pediatr Transpl 2000;4:67-71.
335. deBruyn JC, Chan AK, Bhargava R, Idikio H, Huynh HQ. Liver failure in mitochondrial DNA depletion syndrome: the importance of serial neuroimaging in liver transplantation evaluation. J Pediatr Gastroenter Nutr 2007;45:252-256.
336. Dimmock DP, Dunn JK, Feigenbaum A, Rupar A, Horvath R, Freisinger P, et al. Abnormal neurological features predict poor survival and should preclude liver transplantation in patients with deoxyguanosine kinase deficiency. Liver Transpl 2008;14:1480-1485.
337. Hanchard NA, Shchelochkov OA, Roy A, Wiszniewska J, Wang J, Popek EJ, et al. Deoxyguanosine kinase deficiency presenting as neonatal hemochromatosis. Mol Genet Metab 2011;103:262-267.
338. Srinath A, Shneider BL. Congenital hepatic fibrosis and autosomal recessive polycystic kidney disease. J Pediatr Gastroenter Nutr 2012;54:580-7.
339. Gunay-Aygun M, Font-Montgomery E, Lukose L, Tuchman Gerstein M, Piwnica-Worms K, Choyke P, et al. Characteristics of congenital hepatic fibrosis in a large cohort of patients with autosomal recessive polycystic kidney disease. Gastroenterology 2013;144:112-121 e2.
340. Chapal M, Debout A, Dufay A, Salomon R, Roussey G, Burtey S, et al. Kidney and liver transplantation in patients with autosomal recessive polycystic kidney disease: a multicentric study. Nephrol Dial Transpl 2012;27:2083-2088.
341. Ko JS, Yi NJ, Suh KS, Seo JK. Pediatric liver transplantation for fibropolycystic liver disease. Pediatr Transpl 2012;16:195-200.
342. Mazariegos GV, Soltys K, Bond G, Girnita A, Machaidze Z, Jaffe R, et al. Pediatric intestinal retransplantation: techniques, management, and outcomes. Transplantation 2008;86:1777-1782.
343. Botha JF, Grant WJ, Torres C, Iverson AK, Sudan DL, Shaw BW Jr, et al. Isolated liver transplantation in infants with endstage liver disease due to short bowel syndrome. Liver Transpl 2006;12:1062-1066.
344. Taha AM, Sharif K, Johnson T, Clarke S, Murphy MS, Gupte GL. Long-term outcomes of isolated liver transplantation for short bowel syndrome and intestinal failure-associated liver disease. J Pediatr Gastroenter Nutr 2012;54:547-551.
345. Cavicchi M, Beau P, Crenn P, Degott C, Messing B. Prevalence of liver disease and contributing factors in patients receiving home parenteral nutrition for permanent intestinal failure. Ann Intern Med 2000;132:525-532.
346. Cober MP, Teitelbaum DH. Prevention of parenteral nutrition-associated liver disease: lipid minimization. Curr Opin Organ Transpl 2010;15:330-333.
347. Rudolph JA, Squires R. Current concepts in the medical management of pediatric intestinal failure. Curr Opin Organ Transpl 2010;15:324-329.
348. Fallon EM, Le HD, Puder M. Prevention of parenteral nutrition-associated liver disease: role of omega-3 fish oil. Curr Opin Organ Transpl 2010;15:334-340.
349. Soden JS, Lovell MA, Brown K, Partrick DA, Sokol RJ. Failure of resolution of portal fibrosis during omega-3 fatty acid lipid emulsion therapy in two patients with irreversible intestinal failure. J Pediatr 2010;156:327-331.
350. Pacifico L, Nobili V, Anania C, Verdecchia P, Chiesa C. Pediatric nonalcoholic fatty liver disease, metabolic syndrome and cardiovascular risk. World J Gastroenterol 2011;17:3082-3091.
351. Lapecorella M, Mariani G. Factor VII deficiency: defining the clinical picture and optimizing therapeutic options. Haemophilia 2008;14:1170-1175.
352. Mariani G, Bernardi F. Factor VII Deficiency. Semin Thromb Hemost 2009;35:400-406.
353. Levi D, Pefkarou A, Fort JA, DeFaria W, Tzakis AG. Liver transplantation for factor VII deficiency. Transplantation 2001;72:1836-1837.
354. Muiesan P, Jassem W, Girlanda R, Steinberg R, Vilca-Melendez H, Mieli-Vergani G, et al. Segmental liver transplantation from non-heart beating donors-an early experience with implications for the future. Am J Transpl 2006;6(5 Pt 1):1012-1016.
355. Horita K, Matsunami H, Shimizu Y, Shimizu A, Kurimoto M, Suzuki K, et al. Treatment of a patient with hemophilia A and hepatitis C virus-related cirrhosis by living-related liver transplantation from an obligate carrier donor. Transplantation 2002;73:1909-1912.
356. Chalmers E, Cooper P, Forman K, Grimley C, Khair K, Minford A, et al. Purpura fulminans: recognition, diagnosis and management. Arch Dis Child 2011;96:1066-1071.
357. de Kort EH, Vrancken SL, van Heijst AF, Binkhorst M, Cuppen MP, Brons PP. Long-term subcutaneous protein C replacement in neonatal severe protein C deficiency. Pediatrics 2011;127:e1338-1342.
358. Pescatore SL. Clinical management of protein C deficiency. Exp Opin Pharmacother 2001;2:431-439.
359. Florman SS, Fishbein TM, Schiano T, Letizia A, Fennelly E, DeSancho M. Multivisceral transplantation for portal hypertension and diffuse mesenteric thrombosis caused by protein C deficiency. Transplantation 2002;74:406-407.
360. Darwish Murad S, Plessier A, Hernandez-Guerra M, Fabris F, Eapen CE, Bahr MJ, et al. Etiology, management, and outcome of the Budd-Chiari syndrome. Ann Intern Med 2009;151:167-175.
361. DeLeve LD, Valla DC, Garcia-Tsao G, American Association for the Study Liver D. Vascular disorders of the liver. Hepatology 2009;49:1729-1764.
362. Darwish Murad S, Valla DC, de Groen PC, Zeitoun G, Hopmans JA, Haagsma EB, et al. Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome. Hepatology 2004;39:500-508.
363. Garcia-Pagan JC, Heydtmann M, Raffa S, Plessier A, Murad S, Fabris F, et al. TIPS for Budd-Chiari syndrome: long-term results and prognostics factors in 124 patients. Gastroenterology 2008;135:808-815.
364. Carnevale FC, Santos AC, Tannuri U, Cerri GG. Hepatic veins and inferior vena cava thrombosis in a child treated by transjugular intrahepatic portosystemic shunt. Cardiovasc Intervent Radiol 2010;33:627-630.
365. Singer AL, Locke JE, Stewart ZA, Lonze BE, Hamilton JP, Scudiere JR, et al. Successful liver transplantation for Budd-Chiari syndrome in a patient with paroxysmal nocturnal hemoglobinuria treated with the anti-complement antibody eculizumab. Liver Transpl 2009;15:540-543.
366. Chinnakotla S, Klintmalm GB, Kim P, Tomiyama K, Klintmalm E, Davis GL, et al. Long-term follow-up of liver transplantation for Budd-Chiari syndrome with antithrombotic therapy based on the etiology. Transplantation 2011;92:341-345.
367. Darwish Murad S, Kamath PS. Liver transplantation for Budd-Chiari syndrome: when is it really necessary? Liver Transpl 2008;14:133-135.
368. Mackiewicz A, Kotulski M, Zieniewicz K, Krawczyk M. Results of liver transplantation in the treatment of Budd-Chiari syndrome. Ann Transpl 2012;17:5-10.
369. Cauchi JA, Oliff S, Baumann U, Mirza D, Kelly DA, Hewitson J, et al. The Budd-Chiari syndrome in children: the spectrum of management. J Pediatr Surg 2006;41:1919-1923.
370. Schouten JN, Garcia-Pagan JC, Valla DC, Janssen HL. Idiopathic noncirrhotic portal hypertension. Hepatology 2011;54:1071-1081.
371. de Ville de Goyet J, D'Ambrosio G, Grimaldi C. Surgical management of portal hypertension in children. Semin Pediatr Surg 2012;21:219-232.
372. Kaymakoglu S, Kahraman T, Kudat H, Demir K, Cakaloglu Y, Adalet I, et al. Hepatopulmonary syndrome in noncirrhotic portal hypertensive patients. Dig Dis Sci 2003;48:556-560.
373. De BK, Sen S, Sanyal R. Hepatopulmonary syndrome in noncirrhotic portal hypertension. Ann Intern Med 2000;132:924.
374. Sarin SK, Gupta N, Jha SK, Agrawal A, Mishra SR, Sharma BC, et al. Equal efficacy of endoscopic variceal ligation and propranolol in preventing variceal bleeding in patients with noncirrhotic portal hypertension. Gastroenterology 2010;139:1238-1245.
375. Geramizadeh B, Malek-Hosseini SA, Salahi H, Bahador A, Nikeghbalian S. Liver failure and the need for transplantation in three patients with hepatoportal sclerosis. Transpl Proc 2008;40:3526-3528.
376. Krasinskas AM, Eghtesad B, Kamath PS, Demetris AJ, Abraham SC. Liver transplantation for severe intrahepatic noncirrhotic portal hypertension. Liver Transpl 2005;11:627-634; discussion 10-11.
377. Maganty K, Ghanta R, Bejarano P, Weppler D, Tekin A, Moon J, et al. Liver transplantation for hepatopulmonary syndrome due to noncirrhotic portal hypertension. Transpl Proc 2011;43:2814-2816.
378. Tateo M, Sebagh M, Bralet MP, Teicher E, Azoulay D, Mallet V, et al. A new indication for liver transplantation: nodular regenerative hyperplasia in human immunodeficiency virus-infected patients. Liver Transpl 2008;14:1194-1198.
379. Gupta NA, Abramowsky C, Pillen T, Redd D, Fasola C, Heffron T, et al. Pediatric hepatopulmonary syndrome is seen with polysplenia/interrupted inferior vena cava and without cirrhosis. Liver Transpl 2007;13:680-686.
380. Baichi MM, Arifuddin RM, Mantry PS, Bozorgzadeh A, Ryan C. Liver transplantation in sickle cell anemia: a case of acute sickle cell intrahepatic cholestasis and a case of sclerosing cholangitis. Transplantation 2005;80:1630-1632.
381. Hurtova M, Bachir D, Lee K, Calderaro J, Decaens T, Kluger MD, et al. Transplantation for liver failure in patients with sickle cell disease: challenging but feasible. Liver Transpl 2011;17:381-392.
382. Mekeel KL, Langham MR Jr, Gonzalez-Peralta R, Fujita S, Hemming AW. Liver transplantation in children with sickle-cell disease. Liver Transpl 2007;13:505-508.
383. Krowka MJ. Hepatopulmonary syndromes. Gut 2000;46:1-4.
384. Al-Hussaini A, Taylor RM, Samyn M, Bansal S, Heaton N, Rela M, et al. Long-term outcome and management of hepatopulmonary syndrome in children. Pediatr Transpl 2010;14:276-282.
385. Willis AD, Miloh TA, Arnon R, Iyer KR, Suchy FJ, Kerkar N. Hepatopulmonary syndrome in children - is conventional liver transplantation always needed? Clin Transplant 2011;25:849-855.
386. Kochar R, Tanikella R, Fallon MB. Serial pulse oximetry in hepatopulmonary syndrome. Dig Dis Sci 2011;56:1862-1868.
387. Roberts DN, Arguedas MR, Fallon MB. Cost-effectiveness of screening for hepatopulmonary syndrome in liver transplant candidates. Liver Transpl 2007;13:206-214.
388. Schenk P, Schoniger-Hekele M, Fuhrmann V, Madl C, Silberhumer G, Muller C. Prognostic significance of the hepatopulmonary syndrome in patients with cirrhosis. Gastroenterology 2003;125:1042-1052.
389. Fallon MB, Krowka MJ, Brown RS, Trotter JF, Zacks S, Roberts KE, et al. Impact of hepatopulmonary syndrome on quality of life and survival in liver transplant candidates. Gastroenterology 2008;135:1168-1175.
390. Swanson KL, Wiesner RH, Krowka MJ. Natural history of hepatopulmonary syndrome: impact of liver transplantation. Hepatology 2005;41:1122-1129.
391. Alonso J, Sierre S, Lipsich J, Questa H, Faella H, Moguillansky S. Endovascular treatment of congenital portal vein fistulas with the Amplatzer occlusion device. J Vasc Interv Radiol 2004;15:989-993.
392. Alvarez AE, Ribeiro AF, Hessel G, Baracat J, Ribeiro JD. Abernethy malformation: one of the etiologies of hepatopulmonary syndrome. Pediatr Pulmonol 2002;34:391-394.
393. Grimaldi C, Monti L, Falappa P, d'Ambrosio G, Manca A, de Ville de Goyet J. Congenital intrahepatic portohepatic shunt managed by interventional radiologic occlusion: a case report and literature review. J Pediatr Surg 2012;47:e27-31.
394. Morikawa N, Honna T, Kuroda T, Kitano Y, Fuchimoto Y, Kawashima N, et al. Resolution of hepatopulmonary syndrome after ligation of a portosystemic shunt in a pediatric patient with an Abernethy malformation. J Pediatr Surg 2008;43:e35-38.
395. Iqbal CW, Krowka MJ, Pham TH, Freese DK, El Youssef M, Ishitani MB. Liver transplantation for pulmonary vascular complications of pediatric endstage liver disease. J Pediatr Surg 2008;43:1813-1820.
396. Whitworth JR, Ivy DD, Gralla J, Narkewicz MR, Sokol RJ. Pulmonary vascular complications in asymptomatic children with portal hypertension. J Pediatr Gastroenter Nutr 2009;49:607-612.
397. Rodriguez-Roisin R, Krowka MJ, Herve P, Fallon MB. Pulmonary-hepatic vascular disorders (PHD). Eur Respir J 2004;24:861-880.
398. Laving A, Khanna A, Rubin L, Ing F, Dohil R, Lavine JE. Successful liver transplantation in a child with severe portopulmonary hypertension treated with epoprostenol. J Pediatr Gastroenter Nutr 2005;41:466-468.
399. Safdar Z, Bartolome S, Sussman N. Portopulmonary hypertension: an update. Liver Transpl 2012;18:881-891.
400. Fox AN, Brown RS Jr. Is the patient a candidate for liver transplantation? Clin Liver Dis 2012;16:435-448.
401. Ahmed A, Keeffe EB. Current indications and contraindications for liver transplantation. Clin Liver Dis 2007;11:227-247.
402. Watt KD, Pedersen RA, Kremers WK, Heimbach JK, Sanchez W, Gores GJ. Long-term probability of and mortality from de novo malignancy after liver transplantation. Gastroenterology 2009;137:2010-2017.
403. Chan G, Kocha W, Reid R, Taqi A, Wall W, Quan D. Liver transplantation for symptomatic liver metastases of neuroendocrine tumours. Curr Oncol 2012;19:217-221.
404. Kerkar N, Emre S. Issues unique to pediatric liver transplantation. Clin Liver Dis 2007;11:323-335.
405. McGoogan KE, Haafiz AB, Gonzalez Peralta RP. Herpes simplex virus hepatitis in infants: clinical outcomes and correlates of disease severity. J Pediatr 2011;159:608-611.
406. Verma A, Dhawan A, Zuckerman M, Hadzic N, Baker AJ, Mieli-Vergani G. Neonatal herpes simplex virus infection presenting as acute liver failure: prevalent role of herpes simplex virus type I. J Pediatr Gastroenter Nutr 2006;42:282-286.
407. Patterson MC, Hendriksz CJ, Walterfang M, Sedel F, Vanier MT, Wijburg F. Recommendations for the diagnosis and management of Niemann-Pick disease type C: an update. Mol Genet Metab 2012;106:330-344.
408. Vanier MT. Niemann-Pick disease type C. Orphanet J Rare Dis 2010;5:16.
409. Vanier MT, Wenger DA, Comly ME, Rousson R, Brady RO, Pentchev PG. Niemann-Pick disease group C: clinical variability and diagnosis based on defective cholesterol esterification. A collaborative study on 70 patients. Clin Genet 1988;33:331-348.
410. Yerushalmi B, Sokol RJ, Narkewicz MR, Smith D, Ashmead JW, Wenger DA. Niemann-pick disease type C in neonatal cholestasis at a North American Center. J Pediatr Gastroenter Nutr 2002;35:44-50.
411. Kelly DA, Portmann B, Mowat AP, Sherlock S, Lake BD. Niemann-Pick disease type C: diagnosis and outcome in children, with particular reference to liver disease. J Pediatr 1993;123:242-247.
412. Gartner JC Jr, Bergman I, Malatack JJ, Zitelli BJ, Jaffe R, Watkins JB, et al. Progression of neurovisceral storage disease with supranuclear ophthalmoplegia following orthotopic liver transplantation. Pediatrics 1986;77:104-106.
413. Henter JI. Biology and treatment of familial hemophagocytic lymphohistiocytosis: importance of perforin in lymphocyte-mediated cytotoxicity and triggering of apoptosis. Med Pediatr Oncol 2002;38:305-309.
414. Henter JI, Arico M, Elinder G, Imashuku S, Janka G. Familial hemophagocytic lymphohistiocytosis. Primary hemophagocytic lymphohistiocytosis. Hematol Oncol Clin N Am 1998;12:417-433.
415. Nitta A, Suzumura H, Watabe Y, Okuya M, Nakajima D, Kurosawa H, et al. Fetal hemophagocytic lymphohistiocytosis in a premature infant. J Pediatr 2007;151:98.
416. Parizhskaya M, Reyes J, Jaffe R. Hemophagocytic syndrome presenting as acute hepatic failure in two infants: clinical overlap with neonatal hemochromatosis. Pediatr Dev Pathol 1999;2:360-366.
417. Shanmugam NP, Bansal S, Greenough A, Verma A, Dhawan A. Neonatal liver failure: aetiologies and management-state of the art. Eur J Pediatr 2011;170:573-581.
418. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000;31:864-871.
419. McDiarmid SV, Anand R, Lindblad AS. Development of a pediatric endstage liver disease score to predict poor outcome in children awaiting liver transplantation. Transplantation 2002;74:173-181.
420. Reyes J. A critical analysis to a critical analysis: breaking the circle of organ allocation in the United States. Liver Transpl 2005;11:737-738.
421. Shneider BL, Neimark E, Frankenberg T, Arnott L, Suchy FJ, Emre S. Critical analysis of the pediatric endstage liver disease scoring system: a single center experience. Liver Transpl 2005;11:788-795.
422. Salvalaggio PR, Neighbors K, Kelly S, Emerick KM, Iyer K, Superina RA, et al. Regional variation and use of exception letters for cadaveric liver allocation in children with chronic liver disease. Am J Transpl 2005;5:1868-1874.
423. Rodriguez-Luna H, Vargas HE, Moss A, Reddy KS, Freeman RB, Mulligan D. Regional variations in peer reviewed liver allocation under the MELD system. Am J Transpl 2005;5:2244-2247.
424. UK Transplant, Donor Organ Sharing Scheme Operating Principles, Liver Transplant Units in the UK and Republic of Ireland. In: Transplant NBa, editor. Available at: http://www.organdonation.nhs.uk/ukt/about_transplants/organ_allocation/liver/liver_organ_sharing_principles/2012.
425. Desschans B, Van Gelder F, Van Hees D, de Rocy J, Monbaliu D, Aerts R, et al. Evolution in allocation rules for renal, hepatic, pancreatic and intestinal grafts. Acta Chir Belg 2008;108:31-34.
426. Neto JS, Carone E, Pugliese RP, Fonseca EA, Porta G, Miura I, et al. Modified pediatric endstage liver disease scoring system and pediatric liver transplantation in Brazil. Liver Transpl 2010;16:426-430.
427. Choi Y, Lee KW, Hong G, Kim H, Park MS, Suh S, et al. Status and Current Problems in the Allocation System for Pediatric Liver Transplantation in Korea. J Korean Soc Transplant 2012;26:196-201.
428. Organ Allocation Protocols: Liver Protocol. Available at: http://www.tsanz.com.au/organallocationprotocols/liverprotocol.asp: The Transplnatation Society of Australia and New Zealand, 2012.
429. Aita K. New organ transplant policies in Japan, including the family-oriented priority donation clause. Transplantation 2011;91:489-491.
430. Thuluvath PJ, Guidinger MK, Fung JJ, Johnson LB, Rayhill SC, Pelletier SJ. Liver transplantation in the United States, 1999-2008. Am J Transpl 2010;10(4 Pt 2):1003-1019.
431. McDiarmid SV, Anand R, Martz K, Millis MJ, Mazariegos G. A multivariate analysis of pre-, peri-, and post-transplant factors affecting outcome after pediatric liver transplantation. Ann Surg 2011;254:145-154.
432. Diamond IR, Fecteau A, Millis JM, Losanoff JE, Ng V, Anand R, et al. Impact of graft type on outcome in pediatric liver transplantation: a report from Studies of Pediatric Liver Transplantation (SPLIT). Ann Surg 2007;246:301-310.
433. Sieders E, Peeters PM, TenVergert EM, Bijleveld CM, de Jong KP, Zwaveling JH, et al. Analysis of survival and morbidity after pediatric liver transplantation with full-size and technical-variant grafts. Transplantation 1999;68:540-545.
434. Furtado A, Tome L, Oliveira FJ, Furtado E, Viana J, Perdigoto R. Sequential liver transplantation. Transpl Proc 1997;29:467-468.
435. Mazariegos GV, Morton DH, Sindhi R, Soltys K, Nayyar N, Bond G, et al. Liver transplantation for classical maple syrup urine disease: long-term follow-up in 37 patients and comparative United Network for Organ Sharing experience. J Pediatr 2012;160:116-121 e1.
436. Saner FH, Treckmann J, Pratschke J, Arbogast H, Rahmel A, Vester U, et al. Early renal failure after domino liver transplantation using organs from donors with primary hyperoxaluria type 1. Transplantation 2010;90:782-785.
437. Casas-Melley AT, Thomas PG, Krueger LJ, Falkenstein KP, Flynn LM, Conley SB, et al. Domino as a bridge to definitive liver transplantation in a neonate. Pediatr Transpl 2002;6:249-254.
438. Horslen SP, Fox IJ. Hepatocyte transplantation. Transplantation 2004;77:1481-1486.
439. Lysy PA, Campard D, Smets F, Najimi M, Sokal EM. Stem cells for liver tissue repair: current knowledge and perspectives. World J Gastroenterol 2008;14:864-875.
440. Soltys KA, Soto-Gutierrez A, Nagaya M, Baskin KM, Deutsch M, Ito R, et al. Barriers to the successful treatment of liver disease by hepatocyte transplantation. J Hepatol 2010;53:769-774.